Capital Fund Management S.A. Exact Sciences Corp Call Options Transaction History

Capital Fund Management S.A.

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 13, 2024	BUY	$41.33 - $74.26 $1.53 Million - $2.76 Million	37,100 Added 49.14%	112,600 $4.76 Million
Q1 2024 May 15, 2024	SELL	$56.27 - $73.77 $5.81 Million - $7.62 Million	-103,300 Reduced 57.77%	75,500 $5.21 Million
Q4 2023 Feb 14, 2024	BUY	$59.06 - $75.72 $6.21 Million - $7.97 Million	105,200 Added 142.93%	178,800 $13.2 Million
Q3 2023 Nov 14, 2023	BUY	$65.94 - $99.04 $4.85 Million - $7.29 Million	73,600 New	73,600 $5.02 Million
Q2 2019 Aug 12, 2019	SELL	$89.51 - $118.04 $134,265 - $177,060	-1,500 Reduced 21.43%	5,500 $649,000
Q4 2018 Feb 13, 2019	SELL	$56.04 - $82.66 $358,656 - $529,024	-6,400 Reduced 47.76%	7,000 $442,000
Q3 2018 Nov 14, 2018	BUY	$48.29 - $80.6 $294,569 - $491,659	6,100 Added 83.56%	13,400 $1.06 Million
Q2 2018 Aug 14, 2018	BUY	$37.84 - $69.96 $56,760 - $104,939	1,500 Added 25.86%	7,300 $436,000
Q1 2018 May 15, 2018	SELL	$39.82 - $57.53 $238,920 - $345,180	-6,000 Reduced 50.85%	5,800 $234,000
Q4 2017 Feb 09, 2018	SELL	$46.49 - $60.51 $362,622 - $471,978	-7,800 Reduced 39.8%	11,800 $620,000
Q3 2017 Nov 13, 2017	BUY	$37.05 - $47.12 $726,180 - $923,552	19,600	19,600 $924,000

610

166M

1.93M

1.23M

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $12.1B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.